286007-27-0

Basic information

• Product Name: 3-BROMO-5-(3-METHYLTHIOPHEN-2-YL)PYRIDINE
• Synonyms: 3-BROMO-5-(3-METHYLTHIOPHEN-2-YL)PYRIDINE;5-(3-Thienyl)-3-bromopyridine;3-bromo-5-(3-thienyl)Pyridine
• CAS NO: 286007-27-0
• Molecular Formula: C₉H₆BrNS
• Molecular Weight: 254.14622
• Mol File: 286007-27-0.mol

Chemical Properties

• Melting Point: 58-59℃
• Boiling Point: 299.5°C at 760 mmHg
• Flash Point: 134.9°C
• Appearance: /
• Density: 1.496g/cm³
• Vapor Pressure: 0.00211mmHg at 25°C
• Refractive Index: 1.622
• PKA: 2.79±0.20(Predicted)
• CAS DataBase Reference: 3-BROMO-5-(3-METHYLTHIOPHEN-2-YL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-(3-METHYLTHIOPHEN-2-YL)PYRIDINE(286007-27-0)
• EPA Substance Registry System: 3-BROMO-5-(3-METHYLTHIOPHEN-2-YL)PYRIDINE(286007-27-0)

Safety Data

• Hazardous Substances Data: 286007-27-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-BROMO-5-(3-METHYLTHIOPHEN-2-YL)PYRIDINE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to participate in diverse chemical reactions and transformations. Its unique structure contributes to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-BROMO-5-(3-METHYLTHIOPHEN-2-YL)PYRIDINE serves as a vital component in the creation of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the design of effective compounds targeting specific pests or weeds, enhancing crop protection and yield.

InChI:InChI=1/C10H8BrNS/c1-7-2-3-13-10(7)8-4-9(11)6-12-5-8/h2-6H,1H3

Upstream product

• 872-31-1 3-Bromothiophene 
• 452972-09-7 (5-bromopyridin-3-yl)boronic acid 
• 625-92-3 3,5-dibromopyridine 
• 6165-69-1 Thien-3-ylboronic acid 
• 64-17-5 ethanol 

Downstream Products

• 1216771-29-7 4-(5-(thiophen-3-yl)pyridin-3-yl)benzamide 
• 286007-28-1 1-[(4-methylphenyl)sulfonyl]-3-(5-thien-3-ylpyridin-3-yl)-1H-indole 

Relevant articles and documents

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Design and synthesis of thienylpyridyl garlands as non-peptidic alpha helix mimetics and potential protein-protein interactions disruptors

This paper describes an efficient route leading to new thienylpyridyl garlands as non-peptidic alpha helix mimetics and potential protein-protein interactions disruptors. Firstly, we have studied the reactivity of boronic acids and halogenated pyridines and/or thiophenes towards the Suzuki-Miyaura cross-coupling reaction in order to obtain bis-thienylpyridines. Secondly, we have functionalized these compounds by a reaction of bromination and the resultant bis-bromothienylpyridines have been found to undergo iterative Pd-catalyzed coupling based on a pseudo-Garlanding approach with a range of pyridyl boronic acids to produce a new library of thienylpyridyl oligomers.

Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2

5-(Hetero)aryl-3-(4-carboxamidophenyl)-2-aminopyridine inhibitors of CHK2 were identified from high throughput screening of a kinase-focussed compound library. Rapid exploration of the hits through straightforward chemistry established structure-activity relationships and a proposed ATP-competitive binding mode which was verified by X-ray crystallography of several analogues bound to CHK2. Variation of the 5-(hetero)aryl substituent identified bicyclic dioxolane and dioxane groups which improved the affinity and the selectivity of the compounds for CHK2 versus CHK1. The 3-(4-carboxamidophenyl) substituent could be successfully replaced by acyclic ω-aminoalkylamides, which made additional polar interactions within the binding site and led to more potent inhibitors of CHK2. Compounds from this series showed activity in cell-based mechanistic assays for inhibition of CHK2.

Pharmaceutical compositions and methods for use

The present invention relates to diazabicyclic compounds, preferably to N-aryl diazabicyclic compounds. Of particular interest are 2-pyridinyl diazabicyclic compounds, such as (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. Othe

5-Substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6

A series of 5- and 6-substituted and unsubstituted 3-heteroaromatic analogues of nicotine were synthesized in an effort to delineate the structural requirements for selectively inhibiting human cytochrome P-450 (CYP) 2A6, the major nicotine metabolizing enzyme. Thiophene, substituted thiophene, furan, substituted furan, imidazole, substituted imidazole, pyridine, substituted pyridine, thiazole, and quinoline moieties were used to replace the N-methylpyrrolidine ring of nicotine. Bromo and methyl groups were introduced at the 5-position of the pyridine ring and fluoro, chloro, and methoxy groups were placed at the 6-position of the pyridine ring in order to explore the structure-activity relationship (SAR) of inhibition of CYP2A6. The inhibitory activity of the most potent CYP2A6 inhibitors on the functional activity of human cytochrome P450s 3A4, 2E1, 2B6, 2C9, 2C19, and 2D6 was also examined to determine inhibitor selectivity. We identified 36 compounds that were more potent than nicotine at inhibition of coumarin 7-hydroxylase (CYP2A6) activity. We also found a number of compounds to be highly selective for the inhibition of human CYP2A6 versus the other human CYPs examined.

Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors

We have discovered 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as potent inhibitors of KDR kinase activity. This communication details the evolution of this novel class from a potent screening lead of vastly different structure with an emphasis on structural modifications that retained activity and provided improvements in key physical properties. The synthesis and in-depth evaluation of these inhibitors are described.

Pharmaceutical compositions and methods for use

The present invention relates to diazabicyclic compounds, preferably to N-aryl diazabicyclic compounds. Of particular interest are 2-pyridyl diazabicyclic compounds, such as (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. Other

Angiogenesis inhibitors

The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions su